Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling
Open Access
- 1 March 2013
- journal article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. 6, 145-153
- https://doi.org/10.2147/ott.s40914
Abstract
Aims: To explore the inhibitory effects of epigallocatechin gallate (EGCG) on the proliferation of colorectal cancer cells and on the gene expression of Notch signaling. Methods: The colorectal cancer cells and orthotopic colorectal cancer transplant model were treated with EGCG, and MTT assay was used to test the inhibitory role of EGCG in the proliferation of colorectal cancer cells. Results: MTT assay indicated that EGCG inhibited the proliferation of these four cell lines when the time and concentration increased, and EGCG enhanced the apoptotic rate of these four cell lines. The dosage was positively correlated to the apoptotic rate, and EGCG inhibited the proliferation of colorectal cancer cells by influencing cell cycle. In-vivo study suggested that on the seventh day, the volume of tumors reduced after administrating with 5, 10 and 20 mg/kg of EGCG. At the twenty-eighth day, the volume of tumors was significantly different in three EGCG treatment groups as compared to the control group (P < 0.05), and TUNEL assay indicated that the apoptosis of cancer cells in EGCG treated groups was markedly higher than that in the control group (P < 0.05). In these cell lines, the expressions of HES1 and Notch2 in EGCG treated groups were remarkably lower than that in the control group (P < 0.05). The expression of JAG1 decreased in SW480 cells (P = 0.019), HT-29 cells and HCT-8 cells, but increased in LoVo cells at mRNA level. The expression of Notch1 was upregulated in these four cell lines, but its expression was significantly upregulated only in LoVo and SW480 cells (P < 0.05). Conclusion: In-vitro and in-vivo studies showed that EGCG inhibited the proliferation, induced the apoptosis and affected the cell cycle of colorectal cancer cells. After treating with EGCG, the expressions of HES1 and Notch2 was obviously inhibited, this indicated that EGCG inhibited colorectal cancer by inhibiting HES1 and Notch2.Keywords
This publication has 19 references indexed in Scilit:
- EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic CancerPLOS ONE, 2012
- A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumorTumor Biology, 2010
- The study of effect of tea polyphenols on microsatellite instability colorectal cancer and its molecular mechanismInternational Journal of Colorectal Disease, 2010
- (-)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and post-translationally suppresses the cell proliferative protein TROP2 in human colorectal cancer cells.2010
- (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cellsCarcinogenesis: Integrative Cancer Research, 2009
- (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cellsCarcinogenesis: Integrative Cancer Research, 2008
- The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cellsBiochemical and Biophysical Research Communications, 2007
- Inhibition of Intestinal Tumorigenesis in Apcmin/+ Mice by (−)-Epigallocatechin-3-Gallate, the Major Catechin in Green TeaCancer Research, 2005
- (−)-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer CellsClinical Cancer Research, 2005
- Green Tea Constituent Epigallocatechin-3-Gallate and Induction of Apoptosis and Cell Cycle Arrest in Human Carcinoma CellsJNCI Journal of the National Cancer Institute, 1997